74702-93-5

Usage

Uses

Used in Pharmacology and Neuroscience Research:
1-(3-Bromophenyl)-1-methylethylamine is used as a research chemical for studying the effects of serotonin, dopamine, and norepinephrine release on the central nervous system. Its psychoactive properties make it a valuable tool for understanding the mechanisms of action of various neurotransmitters and their role in cognitive and emotional processes.
However, due to its potential for abuse and lack of safety data, 1-(3-Bromophenyl)-1-methylethylamine is not suitable for human use and is classified as a controlled substance in many jurisdictions. This classification limits its application to strictly regulated research settings, where its potential benefits and risks can be carefully evaluated and managed.

InChI:InChI=1/C9H12BrN/c1-9(2,11)7-4-3-5-8(10)6-7/h3-6H,11H2,1-2H3

Upstream product

• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 30951-66-7 2-(3-bromophenyl)-2-propanol 
• 6952-59-6 3-cyanobromobenzene 
• 917-54-4 methyllithium 
• 861840-21-3 N-(2-(3-bromophenyl)propan-2-yl)-2-chloroacetamide 

Downstream Products

• 1190380-47-2 4-(2-(3-bromophenyl)propan-2-yl)morpholine 
• 214964-87-1 tert-butyl [2-(3-bromophenyl)propan-2-yl]carbamate 
• 1190380-48-3 benzhydrylidene-[3-(1-methyl-1-morpholin-4-yl-ethyl)-phenyl]-amine 
• 1190374-98-1 3-(1-methyl-1-morpholin-4-yl-ethyl)-phenylamine 
• 676135-18-5 2-(3-bromophenyl)propan-2-amine hydrochloride 
• 1255924-12-9 4-(3,4-dichlorophenyl)-7-(6-(trifluoromethyl)pyridazin-3-yl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 1255924-20-9 4-(3,4-dichlorophenyl)-7-(6-aminopyridazin-3-yl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 1255923-87-5 4-(3,4-dichlorophenyl)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 1255924-95-8 4-(3,4-dichlorophenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 1255924-09-4 4-(3,4-dichlorophenyl)-1,1-dimethyl-7-(pyridazin-3-yl)-1,2,3,4-tetrahydroisoquinoline 
• 1255924-92-5 2-(2-(3-bromophenyl)propan-2-ylamino)-1-(3,4-dichlorophenyl)ethanol 

Relevant academic research and scientific papers

Synthesis of 4H-1,3-Benzoxazines via Metal- and Oxidizing Reagent-Free Aromatic C-H Oxygenation

An unprecedented electrochemical aromatic C-H oxygenation reaction for the synthesis of 4H-1,3-benzoxazines from easily available N-benzylamides is reported. These oxidative cyclization reactions proceed in a transition metal- and oxidizing reagent-free fashion and produce H2 as only theoretical byproduct. Adapting the C-H oxygenation reaction in an electrochemical microreactor has been demonstrated.

ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF

Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.

NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE

Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKKβ and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKKβ. In the formula, R1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.

Pyrrolopyrimidines and Pyrrolopyridines

Compounds of formula I in free or salt or solvate form, wherein X, T1, T3 and T4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES

Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer’s disease and other diseases characterized by deposition of A beta peptide in a mammal.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.